Comments
Drug-maker Intas Pharmaceuticals Ltd announced the launch of Romiplostim in India under the brand name Romy, making therapy for chronic immune thrombocytopenia (ITP) affordable for patients. ITP is an autoimmune blood disorder which leads to low platelet counts.
The newly-launched drug will cost just one-fifth of the price of the current nmedication: The currently available care therapy for chronic ITP costs approximately ₹60,000 per month, while Romy has brought it down to ₹12,000.
Romiplostim represents the standard of care, but has been available only internationally since 2008. It is estimated that around 42,000 patients are diagnosed with ITP in India every year. Less than 10 per cent of patients have access to the treatment, which is required to maintain adequate platelet counts for a longer duration.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.